WTB
KPTI icon

Washington Trust Bank’s Karyopharm Therapeutics KPTI Stock Holding History

Washington Trust Bank’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27
Closed -$4K – 843
2016
Q1 		$4K Hold
27
– – ﹤0.01% 657
2015
Q4 		$5K Buy
27
+7
+35% +$1.52K ﹤0.01% 655
2015
Q3 		$3K Hold
20
– – ﹤0.01% 715
2015
Q2 		$8K Buy
20
+7
+54% +$3.03K ﹤0.01% 689
2015
Q1 		$6K Buy
+13
New +$5.6K ﹤0.01% 720

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Washington Trust Bank's KPTI Position: Q2 2016 in Review

Washington Trust Bank sold out of Karyopharm Therapeutics (KPTI) in Q2 2016, closing a stake of 27 shares — an estimated $4K sold.

Washington Trust Bank first reported a position in KPTI in Q1 2015 and held it in 5 quarters. The position peaked at $8K in Q2 2015. 75 funds tracked by Wall St. Rank hold KPTI as of Q2 2016.

  • Washington Trust Bank reported no remaining Karyopharm Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Washington Trust Bank sold 27 Karyopharm Therapeutics shares in Q2 2016, an estimated $4K.
  • Washington Trust Bank first reported a position in Karyopharm Therapeutics in Q1 2015 and held it in 5 quarters.
  • Washington Trust Bank's Karyopharm Therapeutics position peaked at $8K in Q2 2015.
  • 75 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2016.

Based on Washington Trust Bank's 13F filing for Q2 2016, filed 7 Jul 2016.